Skip to main content

Guillain-Barré Syndrome

Grant M. Reed, DO and John J Whitney, Bachelor of Science in Biochemistry Reviewed 06/2022
 


BASICS

DESCRIPTION

  • A group of acquired autoimmune disorders causing acute peripheral neuropathy and ascending paralysis that progressively worsens for up to 4 weeks followed by a slow spontaneous recov...

DIAGNOSIS

HISTORY

  • AIDP presents with onset of progressive limb weakness that reaches its worst within 4 weeks (73% reach a functional nadir in 1 week; 98% by 1 month).

  • Preceding respiratory or gastroint...

TREATMENT

GENERAL MEASURES

  • Consider admission to ensure that disease does not progress (respiratory function; autonomic stability; paralysis).

  • Supportive care is essential, paying close attention to com...

ONGOING CARE

FOLLOW-UP RECOMMENDATIONS

Patient Monitoring

  • Patients require close monitoring of respiratory, cardiac, and hemodynamic function, typically in the ICU setting.

  • Pulmonary function testing (VC...

REFERENCES

1
Liu  J, Wang  LN, McNicol  ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database Syst Rev.  2015;(4):CD009950.  [View Abstract] ...

ADDITIONAL READING

  • Shao S, Wang C, Chang KC, et al. Guillain-Barre Syndrome Associated with COVID-19 Vaccination. Emerg Inf Dis. 2021 Oct 14;27(12).

  • ...

CODES

ICD10

G61.0 Guillain-Barré syndrome 

SNOMED

40956001 Guillain-Barre syndrome (disorder) 

CLINICAL PEARLS

  • Suspect GBS in cases of ascending flaccid paralysis with areflexia and an antecedent history of viral respiratory illness or gastroenteritis.

  • When GBS is suspected, evaluate VC and insp...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

×